CA
NZ
UK
AU
IND
US
Tyra Biosciences, Inc. filed its quarterly report on Form 10-Q with the SEC on November 10, 2026, covering the fiscal quarter and nine months ended September 30, 2026, disclosing a net loss of $135.985 million for the nine-month period and reporting total assets of …
Cingulate Inc. filed a Form 8-K on November 10, 2026, disclosing the status of its CTx-1301 new drug application resubmission following an FDA Complete Response Letter, with a resubmission window targeted between December 2026 and January 2027.
Coursera, Inc. filed a Form 8-K on November 10, 2026, disclosing a workforce reduction plan committed on November 9, 2026, in connection with its merger integration with Udemy, Inc.
Coya Therapeutics, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 10, 2026, reporting financial results for the three and nine months ended that date.
Lichen International Limited filed a Form 6-K on November 10, 2026, reporting that shareholders approved all three proposals at an extraordinary general meeting held on November 9, 2026, including a 100-for-1 share consolidation set to take effect on November 19, 2026.
Aviat Networks, Inc. filed its Form 10-Q with the SEC on November 10, 2026, covering the quarterly period ended October 2, 2026, and reporting a net loss of $2,815 thousand compared with net income of $162 thousand in the prior-year quarter.
Allot Ltd. officer Eyal Harari filed a Form 144 notice of proposed sale of 28,923 ordinary shares, dated November 9, 2026, with the sale to be executed through Oppenheimer & Co. Inc. on Nasdaq.
TriSalus Life Sciences, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 10, 2026, covering the company's financial condition and results of operations for the third quarter.
Ceragon Networks Ltd officer Hadar Vismunski filed a Form 144 notice of proposed sale of 11,775 ordinary shares, with an approximate sale date of November 9, 2026, through broker Oppenheimer & Co. Inc.
Director Peter Linneman filed a Form 4 with the SEC on November 10, 2026, disclosing the acquisition of 324 shares of Regency Centers Corp common stock on November 9, 2026, as director's fees paid in stock.
Please wait processing your request...